These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29473339)

  • 41. Reliability of Thai-Version Overactive Bladder Symptom Scores (OABSS) Questionnaire and the Correlations of OABSS with Voiding Diary, International Prostate Symptom Score (IPSS), and Patient Perception of Bladder Condition (PPBC) Questionnaires.
    Bunyavejchevin S
    J Med Assoc Thai; 2015 Nov; 98(11):1064-74. PubMed ID: 26817176
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of postoperative phosphodiesterase type 5 inhibitor treatment on lower urinary tract symptoms after robot-assisted radical prostatectomy: a longitudinal study.
    Honda M; Kawamoto B; Morizane S; Hikita K; Muraoka K; Sejima T; Takenaka A
    Scand J Urol; 2017 Feb; 51(1):33-37. PubMed ID: 27841089
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pathophysiology and subjective symptoms in women with impaired bladder emptying.
    Gotoh M; Yoshikawa Y; Ohshima S
    Int J Urol; 2006 Aug; 13(8):1053-7. PubMed ID: 16903929
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study.
    Lee SH; Chung BH; Kim SJ; Kim JH; Kim JC; Lee JY
    Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):320-5. PubMed ID: 21788967
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The efficacy of additive tolterodine extended release for 1-year in older men with storage symptoms and clinical benign proastatic hyperplasia.
    Chung SD; Chang HC; Chiu B; Liao CH; Kuo HC
    Neurourol Urodyn; 2011 Apr; 30(4):568-71. PubMed ID: 21344494
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Overactive bladder symptoms and voiding dysfunction in neurologically normal women.
    Espuña-Pons M; Cardozo L; Chapple C; Sievert KD; van Kerrebroeck P; Kirby MG
    Neurourol Urodyn; 2012 Apr; 31(4):422-8. PubMed ID: 22419262
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Is type-2 diabetes mellitus associated with overactive bladder symptoms in men with lower urinary tract symptoms?
    Bang WJ; Lee JY; Koo KC; Hah YS; Lee DH; Cho KS
    Urology; 2014 Sep; 84(3):670-4. PubMed ID: 25168549
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Improvement of voiding characteristics in morbidly obese women after bariatric surgery: A single-center study with a 1-year follow-up.
    Kim JH; Sun HY; Lee HY; Soh MJ; Park S; Kim YJ; Song YS
    Surg Obes Relat Dis; 2017 May; 13(5):836-841. PubMed ID: 28366670
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Variability of post-void residual urine volume and bladder voiding efficiency in patients with underactive bladder.
    Yono M; Ito K; Oyama M; Tanaka T; Irie S; Matsukawa Y; Sekido N; Yoshida M; van Till O; Yamaguchi O
    Low Urin Tract Symptoms; 2021 Jan; 13(1):51-55. PubMed ID: 32525267
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High classification of chronic heart failure increases risk of overactive bladder syndrome and lower urinary tract symptoms.
    Chiu AF; Liao CH; Wang CC; Wang JH; Tsai CH; Kuo HC
    Urology; 2012 Feb; 79(2):260-5. PubMed ID: 22137542
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sacral Nerve Stimulation for Pediatric Lower Urinary Tract Dysfunction: Development of a Standardized Pathway with Objective Urodynamic Outcomes.
    Schober MS; Sulkowski JP; Lu PL; Minneci PC; Deans KJ; Teich S; Alpert SA
    J Urol; 2015 Dec; 194(6):1721-6. PubMed ID: 26141849
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Desmopressin add-on therapy for refractory nocturia in men receiving α-blockers for lower urinary tract symptoms.
    Bae WJ; Bae JH; Kim SW; Chung BH; Kim JH; Kim CS; Lee HM; Lee KS; Yoo TK; Kim SI; Byun SS; Lee JY
    J Urol; 2013 Jul; 190(1):180-6. PubMed ID: 23357213
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictive value of obstructive voiding symptoms and objective bladder emptying tests for urinary retention.
    Jeon S; Yoo EH
    J Obstet Gynaecol; 2012 Nov; 32(8):770-2. PubMed ID: 23075353
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correlation between overactive bladder symptoms and quality of life in Japanese male patients: focus on nocturia.
    Takao T; Tsujimura A; Kiuchi H; Takezawa K; Okuda H; Yamamoto K; Fukuhara S; Miyagawa Y; Nonomura N
    Urology; 2013 Jul; 82(1):189-93. PubMed ID: 23642937
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survey on prevalence of lower urinary tract symptoms in an Asian population.
    Yee CH; Chan CK; Teoh JYC; Chiu PKF; Wong JHM; Chan ESY; Hou SSM; Ng CF
    Hong Kong Med J; 2019 Feb; 25(1):13-20. PubMed ID: 30655460
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Open-label study evaluating outpatient urethral sphincter injections of onabotulinumtoxinA to treat women with urinary retention due to a primary disorder of sphincter relaxation (Fowler's syndrome).
    Panicker JN; Seth JH; Khan S; Gonzales G; Haslam C; Kessler TM; Fowler CJ
    BJU Int; 2016 May; 117(5):809-13. PubMed ID: 26435296
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tamsulosin efficiency in treatment of benign prostatic hyperplasia evaluated by determining bladder weight.
    Milicevic S
    Med Arch; 2012; 66(6):391-5. PubMed ID: 23409519
    [TBL] [Abstract][Full Text] [Related]  

  • 59. GreenLight laser photoselective vaporization of the prostate for treatment of benign prostate hyperplasia/lower urinary tract symptoms in patients with different post-void residual urine.
    Luo F; Sun HH; Su YH; Zhang ZH; Wang YS; Zhao Z; Li J
    Lasers Med Sci; 2017 May; 32(4):895-901. PubMed ID: 28293871
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder.
    Irwin DE; Milsom I; Kopp Z; Abrams P; Artibani W; Herschorn S
    Eur Urol; 2009 Jul; 56(1):14-20. PubMed ID: 19278775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.